Tenatumomab
Modify Date: 2024-09-14 13:36:00
Tenatumomab structure
|
Common Name | Tenatumomab | ||
|---|---|---|---|---|
| CAS Number | 1412891-40-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TenatumomabTenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2]. |
| Name | Tenatumomab |
|---|
| Description | Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2]. |
|---|---|
| Related Catalog | |
| Target |
tenascin-C[1][2] |
| In Vitro | Tenascin-C 是一种在胚胎和成人细胞外基质中发现的六聚体糖蛋白，在恶性实体瘤和血液肿瘤中优先表达。Tenascin-C在空间和时间上与肿瘤新生血管相关，并可能发挥抗粘连和免疫抑制活性[2]。 Tenatumomab (2-5 μg/mL; 16 h) 生物素化后保持免疫反应性。并且每个单抗可以结合多达 20 个生物素，保持 50% 的免疫反应性[2]。 |
| In Vivo | Tenatumomab (4 μg 每鼠; 静脉注射; 单词剂量) 在移植人 HT-29 结肠癌细胞和/或人 U-118MG 胶质母细胞瘤细胞的裸鼠中，分别显示了与低和高张力蛋白表达相关的生物分布[2]。 |
| References |
| No Any Chemical & Physical Properties |